S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
NASDAQ:GMAB

Genmab A/S News Headlines

$44.40
+0.28 (+0.63 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$43.10
Now: $44.40
$44.83
50-Day Range
$37.13
MA: $39.77
$44.12
52-Week Range
$16.24
Now: $44.40
$44.83
Volume1.28 million shs
Average Volume359,458 shs
Market Capitalization$29.10 billion
P/E Ratio34.42
Dividend YieldN/A
Beta0.93

Headlines

Genmab A/S (NASDAQ GMAB) News Headlines Today

Source:
SourceHeadline
Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) AmyloidosisGenmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
finance.yahoo.com - January 15 at 2:28 PM
HC Wainwright Increases Genmab A/S (NASDAQ:GMAB) Price Target to $49.00HC Wainwright Increases Genmab A/S (NASDAQ:GMAB) Price Target to $49.00
americanbankingnews.com - January 15 at 12:47 PM
Genmab A/S (NASDAQ:GMAB) Given Buy Rating at HC WainwrightGenmab A/S (NASDAQ:GMAB) Given Buy Rating at HC Wainwright
americanbankingnews.com - January 15 at 12:47 PM
Emergent BioSolutions Sees Its Composite Rating Rise To 97Emergent BioSolutions Sees Its Composite Rating Rise To 97
finance.yahoo.com - January 13 at 2:29 PM
Genmab A/S (NASDAQ:GMAB) Hits New 1-Year High at $42.51Genmab A/S (NASDAQ:GMAB) Hits New 1-Year High at $42.51
americanbankingnews.com - January 13 at 1:44 PM
Jefferies Financial Group Research Analysts Reduce Earnings Estimates for Genmab A/S (NASDAQ:GMAB)Jefferies Financial Group Research Analysts Reduce Earnings Estimates for Genmab A/S (NASDAQ:GMAB)
americanbankingnews.com - January 11 at 1:40 AM
Genmab A/S (NASDAQ:GMAB) Expected to Post Quarterly Sales of $285.45 MillionGenmab A/S (NASDAQ:GMAB) Expected to Post Quarterly Sales of $285.45 Million
americanbankingnews.com - January 10 at 4:14 AM
 Analysts Expect Genmab A/S (NASDAQ:GMAB) Will Announce Earnings of $0.12 Per Share Analysts Expect Genmab A/S (NASDAQ:GMAB) Will Announce Earnings of $0.12 Per Share
americanbankingnews.com - January 8 at 3:18 PM
Genmab A/S (NASDAQ:GMAB) Hits New 52-Week High on Analyst UpgradeGenmab A/S (NASDAQ:GMAB) Hits New 52-Week High on Analyst Upgrade
americanbankingnews.com - January 5 at 10:12 AM
Genmab A/S (NASDAQ:GMAB) PT Raised to $46.00Genmab A/S (NASDAQ:GMAB) PT Raised to $46.00
americanbankingnews.com - January 4 at 10:01 AM
Genmab A/S (NASDAQ:GMAB) Receives Consensus Rating of "Hold" from AnalystsGenmab A/S (NASDAQ:GMAB) Receives Consensus Rating of "Hold" from Analysts
americanbankingnews.com - December 31 at 3:44 AM
Genmab A/S (NASDAQ:GMAB) Sets New 12-Month High at $40.80Genmab A/S (NASDAQ:GMAB) Sets New 12-Month High at $40.80
americanbankingnews.com - December 30 at 11:36 AM
Genmab: An European R&D Behemoth With Long-Term PotentialGenmab: An European R&D Behemoth With Long-Term Potential
seekingalpha.com - December 24 at 10:29 PM
Dow Jones Rises, Nasdaq Hits New High Amid Stimulus HopesDow Jones Rises, Nasdaq Hits New High Amid Stimulus Hopes
finance.yahoo.com - December 17 at 4:30 PM
Genmab A/S: Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in GenmabGenmab A/S: Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
bloomberg.com - December 16 at 10:39 PM
Is GMAB A Good Stock To Buy Now?Is GMAB A Good Stock To Buy Now?
finance.yahoo.com - December 16 at 10:39 PM
Intra-Cellular Therapies Getting Closer To Key Technical BenchmarkIntra-Cellular Therapies Getting Closer To Key Technical Benchmark
finance.yahoo.com - December 14 at 2:15 PM
Genmab A/S (GMAB) CEO Jan van de Winkel on Q3 2020 Results - Earnings Call TranscriptGenmab A/S (GMAB) CEO Jan van de Winkel on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 5 at 6:12 AM
Genmab A/S EPS beats by DKK1.88, beats on revenueGenmab A/S EPS beats by DKK1.88, beats on revenue
seekingalpha.com - November 4 at 5:39 PM
Genmab Announces Financial Results for the First Nine Months of 2020Genmab Announces Financial Results for the First Nine Months of 2020
finance.yahoo.com - November 4 at 12:38 PM
ADC Therapeutics SA: Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)ADC Therapeutics SA: Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
finanznachrichten.de - October 30 at 7:33 AM
Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
finance.yahoo.com - October 30 at 7:33 AM
Sarepta Therapeutics Clears Key Benchmark, Hitting 80-Plus RS RatingSarepta Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating
finance.yahoo.com - October 29 at 3:02 PM
J&Js daratumumab extends progression-free survival in first-line multiple myelomaJ&J's daratumumab extends progression-free survival in first-line multiple myeloma
seekingalpha.com - October 22 at 1:11 PM
J&Js daratumumab extends survival in first-line multiple myelomaJ&J's daratumumab extends survival in first-line multiple myeloma
seekingalpha.com - October 21 at 7:21 PM
Genmab to Host Capital Markets DayGenmab to Host Capital Markets Day
uk.finance.yahoo.com - October 15 at 11:25 PM
Genmab Announces Data to be Presented at SITC 35th Anniversary Annual MeetingGenmab Announces Data to be Presented at SITC 35th Anniversary Annual Meeting
uk.finance.yahoo.com - October 15 at 12:02 AM
Genmab Commences Binding Arbitration of Two Matters Under License Agreement with JanssenGenmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen
finance.yahoo.com - September 22 at 6:10 PM
Genmab A/S: Genmab to Present at Morgan Stanley 18th Annual Global Healthcare ConferenceGenmab A/S: Genmab to Present at Morgan Stanley 18th Annual Global Healthcare Conference
bloomberg.com - September 12 at 12:13 AM
Strange: Bullish GMAB Analysts Actually See -2.96% DownsideStrange: Bullish GMAB Analysts Actually See -2.96% Downside
nasdaq.com - August 24 at 12:29 PM
Genmab Announces Plan to Transition Arzerra(R) (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S.Genmab Announces Plan to Transition Arzerra(R) (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S.
marketwatch.com - August 22 at 8:03 AM
Genmab A/S (GMAB) CEO Jan van de Winkel on Q2 2020 Results - Earnings Call TranscriptGenmab A/S (GMAB) CEO Jan van de Winkel on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 13 at 1:35 AM
Genmab A/S: U.S. FDA Extends Review of sBLA, Submitted by Novartis, for Ofatumumab in Relapsing Multiple SclerosisGenmab A/S: U.S. FDA Extends Review of sBLA, Submitted by Novartis, for Ofatumumab in Relapsing Multiple Sclerosis
bloomberg.com - August 7 at 12:47 PM
J&Js subcutaneous daratumumab on par with IV version in multiple myeloma studyJ&J's subcutaneous daratumumab on par with IV version in multiple myeloma study
seekingalpha.com - July 31 at 9:07 PM
Disentangling the effect of Covid-19 on Genmab A/ss share priceDisentangling the effect of Covid-19 on Genmab A/s's share price
uk.finance.yahoo.com - July 23 at 4:47 PM
GMAB Crosses Above Average Analyst TargetGMAB Crosses Above Average Analyst Target
www.nasdaq.com - July 23 at 11:46 AM
J&Js Darzalex Q2 sales up 16%J&J's Darzalex Q2 sales up 16%
seekingalpha.com - July 16 at 9:22 AM
Hedge Funds Keep Buying Genmab A/S (GMAB)Hedge Funds Keep Buying Genmab A/S (GMAB)
finance.yahoo.com - June 26 at 12:48 PM
AbbVie in Genmab Cancer Pact That Could Be Worth Over $3 BillionAbbVie in Genmab Cancer Pact That Could Be Worth Over $3 Billion
www.bloomberg.com - June 10 at 7:35 AM
AbbVie Signs Broad Collaboration Agreement With Denmarks Genmab - Quick FactsAbbVie Signs Broad Collaboration Agreement With Denmark's Genmab - Quick Facts
www.nasdaq.com - June 10 at 7:35 AM
AbbVie teams up with Genmab in cancerAbbVie teams up with Genmab in cancer
seekingalpha.com - June 10 at 7:35 AM
Genmabs stock surges after drug development deal with AbbView valued at up to nearly $4 billionGenmab's stock surges after drug development deal with AbbView valued at up to nearly $4 billion
finance.yahoo.com - June 10 at 7:35 AM
AbbVie and Genmab Ink $4 Billion Cancer-Treatment PactAbbVie and Genmab Ink $4 Billion Cancer-Treatment Pact
finance.yahoo.com - June 10 at 7:35 AM
BRIEF-Genmab Announces European Marketing Authorization For Subcutaneous Formulation Of Darzalex®BRIEF-Genmab Announces European Marketing Authorization For Subcutaneous Formulation Of Darzalex®
www.reuters.com - June 5 at 12:02 AM
Genmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-chain (AL) AmyloidosisGenmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-chain (AL) Amyloidosis
uk.finance.yahoo.com - May 28 at 11:14 PM
BRIEF-Tavotek Biotherapeutics Enters Into Research Agreement With Genmab A/S To Develop Bispecific AntibodiesBRIEF-Tavotek Biotherapeutics Enters Into Research Agreement With Genmab A/S To Develop Bispecific Antibodies
www.reuters.com - May 25 at 7:39 PM
Genmab's Shares March Higher, Can It Continue?Genmab's Shares March Higher, Can It Continue?
finance.yahoo.com - May 20 at 9:06 AM
Genmab Reaches Analyst Target PriceGenmab Reaches Analyst Target Price
www.nasdaq.com - May 19 at 1:04 PM
Genmab Announces Data to be Presented at the EHA25 Virtual CongressGenmab Announces Data to be Presented at the EHA25 Virtual Congress
www.benzinga.com - May 14 at 12:00 PM
GMAB Genmab A/S ADSGMAB Genmab A/S ADS
www.nasdaq.com - May 7 at 6:50 PM
This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.